(MENAFN- Baystreet)
Pixelworks Hitches Wagon to Disney's Star
NeuroSense Flat on New ALS Treatment
JetBlue Airways Reports Net Loss Of $104 Million
Toyota and Volkswagen: Auto Sales Kings in 2023
General Motors' Stock Rises 7% On Q4 Earnings Beat Previous Articles Subscribe to Get Small Cap News & Alerts
Baystreet Staf - Tuesday, January 30, 2024
Drugmaker Pfizer Reports Surprise Q4 Profit
Pfizer (PFE) has reported a surprise profit for the fourth quarter of 2023 as sales of its Covid-19 medications performed better than expected.
The drugmaker reported Q4 earnings per share (EPS) of $0.10 U.S. compared to a loss of $0.22 U.S. that had been expected.
Revenue in the quarter totaled $14.25 billion U.S. versus $14.42 billion U.S. that was forecast on Wall Street. Overall sales were down 41% from a year earlier.
Pfizer's Covid-19 vaccine sales totaled $5.36 billion U.S. in Q4, down 53% from a year earlier. But that result was better than the $4.99 billion U.S. in Covid-19 sales expected on Wall Street.
Pfizer has struggled with a rapid decline in its Covid-19 business, where demand has dropped as the medications transitioned to the commercial market.
Looking forward, the pharmaceutical company reiterated its full-year 2024 guidance that calls for revenue of $58.50 billion U.S. to $61.50 billion U.S.
Pfizer said that it expects 2024 earnings of $2.05 U.S. to $2.25 U.S. per share.
In addition to declining sales of its Covid-19 medications, Pfizer has also struggled to develop a weight loss drug, scrapping a planned weight loss pill after poor clinical trial results.
Pfizer said it hopes that its $34 billion U.S. acquisition of cancer drugmaker Seagen, which closed during Q4 of last year, will restore investor confidence.
The stock of Pfizer has declined 37% over the last 12 months to trade at $27.48 U.S. per share.
About Us Contact Us Advertise License Our Content Jobs Disclaimer Privacy Policy
Copyright 1998 - 2024 Baystreet Media Corp. All rights reserved. Nasdaq Stocks: Information delayed 15 minutes. Non-Nasdaq Stocks: Information delayed 20 minutes. Bid and Ask quotation information for NYSE and AMEX securities is only available on a real time basis. Market Data is provided by QuoteMedia. Earnings by Zacks. Analyst Ratings by Zacks
MENAFN30012024000212011056ID1107787279
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.